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Arterial access site utilization in cardiogenic shock in the
United Kingdom: Is radial access feasible?
Mamas A. Mamas, MA, DPhil, BMBCh, MRCP, a,b ,h,i Simon G. Anderson, a,b,h,i Karim Ratib c,h Helen Routledge, d,h
Ludwig Neyses, b,h Douglas G. Fraser, a,h Iain Buchan, e,h Mark A. de Belder, f,h Peter Ludman, g,h and
Jim Nolan, c,h Manchester, Stoke-on-Trent, Worcester, Middlesbrough, and Birmingham, United KingdomBackground Cardiogenic shock (CS) remains the leading cause of mortality in patients hospitalized with acute
myocardial infarction (AMI). The transradial access site (TRA) has become increasingly adopted as a default access site for
percutaneous coronary intervention (PCI); however, even in experienced centers that favor the radial artery as the primary
access site during PCI, patients presenting in CS are often treated via the transfemoral access site (TFA); and commentators
have suggested that CS remains the final frontier that has given even experienced radial operators pause. We studied the use
of TRA in patients presenting in CS in a nonselected high-risk cohort from the British Cardiovascular Intervention database over
a 7-year period (2006-2012).
Methods Mortality (30-day) and major adverse cardiac and cerebrovascular events (a composite of in-hospital mortality,
in-hospital myocardial reinfarction, target vessel revascularization, and cerebrovascular events) were studied based on TFA
and TRA utilization in CS patients. The influence of access site selection was studied in 7,231 CS patients; TFA was used in
5,354 and TRA in 1,877 patients.
Results Transradial access site was independently associated with a lower 30-day mortality (hazard ratio [HR] 0.56, 95% CI
0.46-0.69, P = 0 b .001), in-hospital major adverse cardiac and cerebrovascular events (HR 0.64, 95% CI 0.53-0.76, P b .0001)
and major bleeding (HR 0.37, 95% CI 0.18-0.73, P = .004).
Conclusions Although the majority of PCI cases performed in patients with cardiogenic shock in the United Kingdom are
performed through the TFA, the radial artery represents an alternative viable access site in this high-risk cohort of patients in
experienced centers. (Am Heart J 2014;167:900-908.e1.)Despite advances in medical therapy, percutaneous
coronary intervention (PCI), and mechanical support
during the past 2 decades, cardiogenic shock remains the
leading cause of mortality in patients hospitalized with
AMI.1 Although the incidence of cardiogenic shock has
decreased over the past 3 decades (from around 7% to
3%),1,2 mortality rates remain significant, with in-hospital
mortality rates of between 30% and 60% reported.1–3
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http://dx.doi.org/10.1016/j.ahj.2014.03.007many as 1 in 10 patients with cardiogenic shock.4 These
major bleeding complications accounted for 14% of 30-
day “noncardiac”mortality in a secondary analysis of the
SHOCK trial. 5
The transradial access site (TRA) has become increasingly
adopted as a default access site for PCI acrossmany centers,
having been shown to reduce major bleeding, access site–
related complications, and mortality. However, even in
experienced centers that favor the radial artery as the
primary access site during PCI, patients presenting in
cardiogenic shock are often treated via the transfemoral
access site (TFA); and commentators have suggested that
cardiogenic shock remains the final frontier that has given
even experienced radial operators pause.6
Most studies that have compared access site–specific
outcomes in patients undergoing PCI have excluded
cardiogenic shock as an indication for the radial approach.7
More recently, small retrospective case series of patients
with cardiogenic shock undergoing PCI in experienced
high-volume radial centers reported that TRA was associ-
ated with a independent reductions in mortality 8,9 in
patients presenting with cardiogenic shock.
However, it remains unclear whether it is feasible to
undertake PCI in patients with cardiogenic shock through
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Volume 167, Number 6the TRA outside of a few such specialist transradial centers
and whether the observed outcomes associated with the
TRA are reproducible nationally. We have studied access
site utilization in patients presenting in cardiogenic
shock undergoing PCI in a nonselected high-risk national
cohort from the British Cardiovascular Intervention
Society (BCIS) database to study changes in access site
utilization over time, the feasibility of TRA access site
utilization in this high-risk cohort of patients, and its
associated outcomes.Methods
The BCIS database
The BCISwas formed in 1988 to collect PCI data relating
to the nationwide practice of PCI in the United Kingdom.
Data are collected via an electronic database under the
auspices of the National Institute of Cardiovascular
Outcomes Research,10 and annual reports are available
for download from the society’s Web site (http://www.
bcis.org.uk) from 1992 onwards. As of December 2012,
there are approximately 569,600 records in the BCIS
database. Mortality tracking is undertaken by the
National Health Service (NHS) Central Register using
the patients’ NHS number that provides a unique
identifier for any person registered with the NHS in
England and Wales.Study definitions
Percutaneous coronary intervention procedures per-
formed in patients with cardiogenic shock in the United
Kingdom between January 2006 and December 2012
were analyzed in this study. Cardiogenic shock is defined
in the BCIS dataset as a blood pressure b100 mm Hg with
pulse N100 beats/min combined with signs of peripheral
hypoperfusion (cold, clammy, pallor, etc), or a require-
ment for inotropes or intraaortic balloon pump (IABP) to
support the circulation and maintain a blood pressure.
Patients who underwent PCI through the left or right
femoral artery or the left or right radial artery were
included in the femoral and radial cohorts, respectively,
whereas patients where the access site was unknownwere
excluded. The primary outcome examined was 30-day
mortality.Major adverse cardiac and cerebrovascular events
(MACCE) were a composite of in-hospital mortality and in-
hospital myocardial reinfarction, target vessel revasculari-
zation, and cerebrovascular events. Cerebrovascular
events were defined as a clinically detected ischemic
stroke, hemorrhagic stroke, or transient ischemic attack
that occurred during or after PCI and before hospital
discharge. In-hospital major bleeding complicationswere
defined as gastrointestinal bleed, intracerebral bleed,
retroperitoneal hematoma, blood or platelet transfusion,
or an arterial access site complication requiring surgery.Statistical analysis
All statistical analyses were performed with the
statistical package Stata/MP version 13.1 (Stata Corp,
College Station, TX).
Data are expressed as arithmetic mean ± SD (or 95% CIs)
and number (percentage) for continuous and categorical
variables, respectively. To compare proportions for
nonparametric data, we used the χ2 test or analysis of
variance. Tests for linear trend used χ2 models. A value of
P b .05 was used to indicate statistical significance.
We used the Stata module teffects ipw to estimate
treatment effects via inverse-probability weighting. In-
verse-probability weighting uses the reciprocal of the
probability of being in the observed treatment group from
fitted models of treatment status. Treatment independent
covariates such as patient demographic factors and
procedural and interaction terms were included in all
models. To ensure the validity of the standard errors, a
bootstrap procedure was applied to the whole process.
To further account for confounding variables and bias,
propensity score methods with nearest neighbor match-
ing were performed on the naive study cohort. A
propensity score was estimated for each episode of radial
or femoral access using a logistic regression model to fit
access site use to patient demographics. Variables
included in the model were age, sex, diabetes, hyperten-
sion, hypercholesterolemia, peripheral vascular disease,
previous stroke (cerebrovascular accident [CVA]), renal
failure, previous AMI, previous PCI, previous coronary
artery bypass graft (CABG), IABP, and ventilation.
Interaction terms for demographic and procedural risk
factors were also included in the model. Mahalanobis
distance matching with the propensity score as the
distance matrix was then undertaken. Standardized
differences between groups were estimated to assess
the balance achieved by matching. A baseline character-
istic was considered to be well balanced if the
standardized difference was b10%.
The relationship of baseline variables and 30-day
mortality and MACCE was assessed by Cox proportional
hazard models in the naive and propensity score methods
cohorts. We constructed bootstrapped multivariate Cox
regression models using factors thought to be important
for the end points and included age, sex, diabetes,
hypertension, hypercholesterolemia, smoking status,
clinical syndrome, previous history of AMI, renal function,
family history, left ventricular function, IABP use, venti-
lation status, access site, glycoprotein (Gp) IIb/IIIa
inhibitor use, and center volume (quartile of radial access
site use) as covariates. For all models, we tested for
interaction by adding terms for access site and relevant
demographic or periprocedural risk factors. Tests for
statistical significance used theWald test of the interaction
terms. If the interaction terms were not significant, they
were excluded from the final models. We evaluated the
predictive power of the Cox regression models by
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rank correlation. In general, a Harrell C value of 0.5 and
a Somers D value of 0 indicate no predictive ability of
the model.
Kaplan-Meier cumulative survival curveswere constructed
and compared by the log-rank test. Multivariate logistic
regression models were constructed to estimate predictors
for the utilization of the TFA vs TRA. The Hosmer and
Lemeshow goodness-of-fit test for logistic regression models
was used to assess the validity of the models. Model
discrimination was quantified by the C statistic. We adjusted
our estimate of the C statistic for optimism using 10-fold
cross-validationwith randomresampling to generate average
predictedprobabilities. Bootstrapping techniqueswere used
to validate the model, that is, to adjust the estimated model
performance for overoptimism or overfitting.
No extramural funding was used to support this work.
The authors are solely responsible for the design and
conduct of this study, all study analyses, the drafting and
editing of the paper, and its final contents.Results
A total of 483,381 eligible PCI procedures were
performed in patients in the United Kingdom between
January 1, 2006, and December 31, 2012, of which 8,222
were performed in patients categorized as presenting
with cardiogenic shock (1.7%). The access site or clinical
indication was unknown or was unclear in 991 (12.0%)
patients; and hence, these were excluded from further
analysis, leaving 7,231 eligible procedures. The most
common clinical syndrome in patients presenting with
cardiogenic shock was primary PCI for ST-elevation
myocardial infarction (4,898/7,231; 67.74%). The mean
age of the patients was 67.2 (66.9-67.5) years (mean
[95% CIs]), and 5,055 (70.1%) were male.
Transfemoral access site was used in 5,354 procedures
(74.0%), whereas TRA was used in 1,877 procedures
(26.0 %). Figure 1 illustrates the trends in access site use
for cardiogenic shock between 2006 and 2012. Transra-
dial access site utilization increased from 9.5% of all
cardiogenic shock cases in 2006 to 34.2% of all cases in
2012 (P value for trend b.0001). A relationship between
utilization of the TRA approach in cases with cardiogenic
shock and total TRA center experience based on
percentage of cases undertaken through TRA approach
was observed (Table I). Whereas only 2,937/7,923
(37.1%) of cases with cardiogenic shock were undertaken
in centers with N50% TRA utilization, 1,172/1,877
(62.4%) of all cardiogenic shock cases treated through
the TRA were performed in these centers.
Table II details the clinical demographic features, and
Table III details the procedural characteristics of patients
with cardiogenic shock undergoing PCI via the TRA site
or the TFA site. The clinical features were similar in bothgroups, although patients treated with the TFA were
more likely to be diabetic, be female, receive an IABP and
inotropic support, or be ventilated. In general, patients
treated with a TFA approach were sicker. Multivariate
predictors from logistic regression models for the
utilization of the TFA site in patients presenting with
cardiogenic shock are presented in Table IV.
Thirty-day mortality in the total cohort was 2,296/6,323
(36.3%), of which 1,934 (39.8%) occurred in those cases
performed though the TFA site, whereas 362 (24.7%)
occurred in those cases performed through the TRA site
(χ2=110.2, P b .001). There were no trends in 30-day
mortality rates by year in the TRA group (P for trend =
.06) for patients with cardiogenic shock; however, rates
have increased in TFA-treated group over time (P for
trend b .0001; Figure 1, B). Figure 2 illustrates unadjusted
Kaplan-Meier survival curves for both the TFA and TRA
site groups, with a statistically significant lower all-cause
mortality associated with the use of TRA (hazard ratio
[HR] 0.54, 95% CI 0.50-0.60, P b .0001).
Bootstrapped multivariate Cox proportional hazard
models adjusted for baseline procedural and demographic
characteristics demonstrated that utilization of the TRA
was independently associated with a lower 30-day
mortality (HR 0.56, 95% CI 0.46-0.69, P = 0 b .001).
When the impact of access site on 30-day mortality was
studied in relation to TRA center experience (based on
percentage of cases undertaken through the TRA ap-
proach), there was no prognostic benefit associated with
TRA if undertaken in a center with the lowest percentage
of TRA cases (0%-25% TRA cases) (HR 0.68, 95% CI 0.45-
1.03, P= .06). In contrast, in centerswhere the proportion
of radial cases was 26% to 50% (HR 0.64, 95% CI 0.48-0.87,
P = .004), 51% to 75% (HR 0.66, 95% CI 0.48-0.90, P =
.008), and N75% (HR 0.50, 95% CI 0.35-0.73, P b .0001),
utilization of the TRAwas independently associatedwith a
lower 30-day mortality. Other multivariate predictors of
30-day mortality outcomes are presented in Table V.
Bootstrapped inverse probability weights were used to
estimate the causal effect of treatment (access site) on
mortality (Table VI). There was an estimated 8% lower
risk of 30-day mortality (odds ratio [OR] 0.92, 95%
CI 0.88-0.97, P = .001) for TRA vs TFA. To further reduce
the potential for confounding variables and bias in our
study cohort, propensity score matching was performed
using nearest neighbor matching to create 2 propensity
score–matched patient cohorts. A propensity score–
matched cohort of 2,804 patients was created—1,402 in
the TFA group and 1,402 in TRA group (online Appendix
Supplementary Table)—with baseline demographics well
balanced in the 2 propensity-matched cohorts. Thirty-day
mortality was 267/1,173 (22.8%) in the TRA cohort and 306/
1,296 (29.9%) in the TFA cohort (P b .001). Multivariate Cox
regression analysis adjusted for baseline procedural and
demographic characteristics demonstrated that TRA was
independently associated with a lower 30-day mortality
Figure 1
A, Utilization (number of cases) of the radial and femoral access site during PCI in patients presenting with cardiogenic shock (January 2006-
December 2012). B, Thirty-day mortality (%) between 2006 and 2012 for radial, **femoral, and **combined cohort in patients with cardiogenic
shock. Test for trend across ordered categorical groups: *P b .05, **P b .0001. C, In-hospital MACCE (%) outcomes between 2006 and
2012 for radial, **femoral, and **combined cohort in patients with cardiogenic shock. Test for trend across ordered categorical groups: *P b .05,
**P b .0001.
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score–matched cohort.
Major adverse cardiac and cerebrovascular events
occurred in 2,180/4,889 (44.9%) in those cases performed
through the TFA site and in 458/1,501 (30.5%) in casesperformed through the TRA (P b .001). Changes in MACCE
over time and according to access site are presented in
Figure 1, C. Multivariate Cox proportional hazard models
adjusted for baseline procedural and demographic
characteristics demonstrated that TRA was independently
Table I. Relationship between access site utilization and TRA
center experience based on percentage of cases undertaken
through TRA approach
≥75% 51%-75% 26%-50% 0%-25% Total
Femoral (n) 629 1136 2139 1450 5354
(%) 52.7 65.2 78.9 91.7 74.0
Radial (n) 565 607 573 132 1877
(%) 47.3 34.8 21.1 8.3 26.0
Total 1194 1743 2712 1582 7231
100 100 100 100 100
Table II. Baseline clinical demographics presented as mean ± SD
or number (percentage) for radial and femoral access site
Variable
Radial
(n = 1877)
Femoral
(n = 5354) P
Clinical presentation
Primary PCI 1246 (66.4) 3652 (68.2)
Rescue PCI 142 (7.6) 453 (8.5) 6.33,
P = .042
NSTEMI/UA 489 (26.1) 1249 (23.3)
Age (y) 67.3 (66.8-67.5) 67.2 (66.7-67.8) 0.74
Gender (male) 1389 (74.2) 3666 (68.7) 20.1,
P b .0001
Diabetes 302 (17.1) 1036 (21.3) 14.15,
P = .002
Hypertension 777 (43.6) 2379 (46.6) 4.72,
P = .030
Hypercholesterolemia 744 (41.7) 2316 (41.8) P = .957
Previous AMI 365 (21.2) 1141 (24.8) 9.16,
P = .001
Previous PCI 176 (9.69) 689 (13.6) 18.17,
P b .0001
Previous CABG 36 (2.0) 295 (5.8) 42.19,
P b .0001
Renal failure 94 (5.5) 429 (9.2) 22.6,
P b .0001
Smoking
Current 484 (30.3) 1270(31.0)
Ex-smoker 577 (36.2) 1381 (33.7) P = .21
Non-smokers 535 (33.5) 1444 (35.3)
NSTEMI, Non–ST-elevation myocardial infarction.
Table III. Procedural characteristics presented as mean ± SD or
number (percentage) for radial and femoral access site
ariable
Radial
(n = 1877)
Femoral
(n = 5354) P
BP 523 (29.0) 1923 (37.8) 44.52, P b .001
otrope use 205 (10.9) 948 (17.7) 47.73, P b .001
entilated 315 (18.6) 1639 (34.0) 141.12, P b .001
p IIb/IIIa 1014 (55.6) 2940 (57.7) 2.46, P = .116
ysis 206 (11.0) 579 (10.8) P = .85
arget vessel
LAD 1012 (54.1) 2744 (52.0) P = .27
LCx 254 (13.6) 756 (14.3) P = .77
RCA 513 (27.4) 1408 (26.7) P = .76
LMS 74 (4.0) 258 (4.9) P = .74
Grafts 17 (0.9) 108 (2.1) P = .28
ES use 912 (48.6) 2443 (45.6) 4.89, P = .027
ean no. of
stents used
1.90 (1.84-1.96) 1.83 (1.79-1.88) P = .18
AD, Left anterior descending; LCx, Left circumflex; RCA, right coronary artery;
LMS, left main stem; DES, drug eluting stent; IABP, intra-aortic balloon pump.
Table IV. Predictors for utilization of the TFA from multivariate
logistic regression
OR 95% CI PNz
Clinical syndrome
NSTEMI/UA 1.00
PPCI 1.31 1.10 1.56 .002
Rescue PCI 1.36 1.00 1.84 .047
Age (per year) 1.00 0.99 1.00 .571
Gender (female) 1.40 1.19 1.64 b.0001
Smoking
Never
Ex 0.86 0.72 1.03 .107
Current 0.86 0.71 1.03 .1
Ventilated (yes) 2.51 2.08 3.04 b.0001
Inotrope use (yes) 1.59 1.27 1.98 b.0001
IABP use (yes) 1.88 1.60 2.22 b.0001
GPI (yes) 1.10 0.95 1.27 .19
Renal disease (yes) 1.49 1.09 2.04 .013
Previous PCI (yes) 1.65 1.28 2.13 b.0001
Previous CABG (yes) 3.39 1.93 5.93 b.0001
Previous MI (yes) 0.99 0.81 1.21 .934
Diabetes (yes) 1.09 0.90 1.32 .369
Bootstrapped logistic regression with Hosmer-Lemeshow: χ2 = 5.39, P = .7153,
C statistic = 0.67.
GPI, Glycoprotein IIb/IIIa inhibitor; PPCI, primary PCI; NSTEMI/UA, non ST-elevation
myocardial infarction/Unstable angina.
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June 2014associated with a lower in-hospital MACCE (HR 0.64, 95%
CI 0.53-0.76,P b .0001). Othermultivariate predictors of in-
hospital MACCE are presented in Table VII. When the
impact of access site on in-hospital MACCE was studied in
relation to TRA center experience (based on percentage of
cases undertaken through TRA approach), there was no
prognostic benefit associated with TRA if undertaken in a
center with the lowest percentage of TRA cases (0%-25%
TRA cases) (HR 0.68, 95%CI 0.44-1.11,P= .13). In contrast,
in centers where the proportion of radial cases was 25% to
50% (HR 0.77, 95% CI 0.62-0.95, P = .02), 50% to 75%
(HR 0.65, 95% CI 0.50-0.85, P b .0001), and N75% (HR 0.51,
95% CI 0.36-0.72, P b .0001), utilization of the TRA was
independently associated with lower in-hospital MACCE.V
IA
In
V
G
L
T
D
M
LIn a model with similar characteristics, inverse probability
weightswere used to estimate the causal effect of treatment
(access site) on MACCE. There was an estimated 6% lower
risk ofMACCE (OR 0.94, 95%CI 0.89-0.98,P= .002) for TRA
vs TFA.
Major bleeding complications occurred in 192/6,494
(3.0%) cases, of which 167/4,798 (3.5%) occurred in those
cases performed through TFA, whereas 25/1,696 (1.5%)
occurred in those cases performed throughTRA (Pb .0001)
(Table VIII). Multivariate Cox regression analyses adjusted
Figure 2
Kaplan-Meier survival curve comparing outcomes of PCI performed in
patients with cardiogenic shock according to access site.
Table V. Multivariate predictors for 30-day mortality using Cox
proportional hazard models
HR 95% CI P
Access site (TRA vs TFA) 0.56 0.46 0.69 b.001
Gender (female vs male) 0.93 0.77 1.12 .425
Age (per year) 1.03 1.02 1.04 b.001
Smoking
Never 1.00
Ex 1.16 0.95 1.41 .148
Current 1.19 0.94 1.50 .146
Hypertension 1.16 0.96 1.40 .131
Hypercholesterolemia 1.09 0.90 1.31 .395
Peripheral vascular disease 1.17 0.92 1.49 .21
Previous CVA 1.19 0.91 1.56 .193
Family history 1.20 1.00 1.43 .046
Previous MI 0.85 0.69 1.05 .123
Previous CABG 1.04 0.71 1.53 .832
Previous PCI 0.99 0.76 1.30 .95
Renal disease 1.39 1.09 1.77 .008
GPI use 0.72 0.61 0.86 b.001
Clinical syndrome
NSTEMI/UA 1.00
PPCI 1.41 1.16 1.72 .001
Rescue PCI 1.34 0.95 1.88 .091
Left ventricular function
Good 1.00
Fair 1.32 1.00 1.75 .048
Poor 2.54 1.94 3.31 b.001
IABP use (yes) 1.16 0.96 1.40 .133
Inotrope use (yes) 1.69 1.35 2.12 b.001
No. of vessels (per unit) 1.06 0.99 1.14 .081
Harrell C concordance = 0.72 and Somers D = 0.44.
Table VI. Inverse probability weighting–derived bootstrapped
treatment effects estimates for 30-day mortality using by access site
(TFA vs TRA)
Rate ratio 95% CI P
TE for radial vs femoral 0.92 0.88 0.97 .001
ender (female vs male) 0.68 0.52 0.90 .007
ge (per year) 1.01 1.00 1.02 .01
moking
Never 1.00
Ex 1.24 0.93 1.65 .135
Current 1.22 0.90 1.65 .204
ypertension 0.77 0.60 0.99 .039
ypercholesterolemia 0.98 0.75 1.28 .903
eripheral vascular disease 0.70 0.45 1.09 .114
revious CVA 1.15 0.80 1.66 .447
amily history 1.45 1.15 1.84 .002
revious MI 0.84 0.61 1.15 .269
revious CABG 0.29 0.12 0.69 .005
revious PCI 0.72 0.49 1.06 .094
enal disease 0.64 0.39 1.05 .076
PI use 0.77 0.63 0.96 .018
linical syndrome
STEMI/UA 1.00
PCI 0.83 0.63 1.09 .177
escue PCI 0.67 0.41 1.10 .114
eft ventricular function
ood 1.00
air 0.82 0.64 1.04 .105
oor 0.87 0.65 1.16 .345
BP use (yes) 0.65 0.51 0.83 .001
notrope use (yes) 0.67 0.50 0.91 .01
umber of vessels (per unit) 1.02 0.92 1.13 .697
ATE, Average treatment effect.
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demonstrated that TRA was independently associated
with a lower rate of major bleeding complications (HR
0.37, 95% CI 0.18-0.73, P = .004).A
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NDiscussion
In the largest analyses of its kind investigating outcomes
in a contemporary cohort of patients with cardiogenic
shock undergoing PCI in the United Kingdom, we
observe that although the majority of PCI cases per-
formed in patients with cardiogenic shock in the United
Kingdom are performed through the TFA, TRA can be used
in many shocked patients and that TRA access site
utilization in cardiogenic shock has grown progressively
from 2006, reflecting the increased adoption of the TRA
within United Kingdom interventional practice over this
time period.11 Our analysis also shows an association
between an operator deciding to use a TRA access site and
lower 30-day mortality, in-hospital MACCE, and major
bleeding complications, although these favorable outcomes
associated with TRA choice in patients with cardiogenic
shock are not observed in centers with very low rates of
TRA experience (b25%). Finally, our observations suggest
that the femoral artery remains the preferred access site in
cases with significant hemodynamic compromise with
independent predictors of TFA utilization including the
presence of severe left ventricular dysfunction, female
gender, inotropic drug use, IABP use, and ventilation.
Although 2 recent small single-center studies have
studied outcomes associated with access site utilization in
Table VII. Multivariate predictors for MACCE using Cox
regression analyses
HR 95% CI PNz
Access site (radial vs femoral) 0.64 0.53 0.76 b.0001
Gender (female vs male) 0.99 0.84 1.17 .908
Age (per year) 1.03 1.02 1.04 b.0001
Smoking
Never 1.00
Ex 1.03 0.86 1.24 .717
Current 1.15 0.94 1.40 .183
Hypertension 1.08 0.92 1.28 .351
Hypercholesterolemia 0.98 0.83 1.15 .783
Peripheral vascular disease 1.34 1.08 1.68 .009
Previous CVA 1.27 1.00 1.61 .053
Family history 1.06 0.91 1.25 .452
Previous MI 0.88 0.73 1.07 .209
Previous CABG 1.06 0.75 1.49 .747
Previous PCI 1.08 0.85 1.38 .538
Renal disease 1.46 1.17 1.82 .001
GPI use 0.75 0.64 0.87 b.0001
Clinical syndrome
NSTEMI/UA 1.00
PPCI 1.53 1.29 1.82 b.0001
Rescue PCI 1.11 0.81 1.51 .526
Left ventricular function
Good 1.00
Fair 1.52 1.19 1.94 .001
Poor 2.59 2.04 3.28 b.0001
IABP use (yes) 1.21 1.02 1.43 .031
Inotrope use (yes) 1.55 1.25 1.91 b.0001
Number of vessels (per unit) 1.06 1.00 1.13 .053
Harrell C concordance = 0.71 and Somers D =0.42.
Table VIII. Bleeding rates according to access site utilization
ariable
Radial
(n = 1877)
Femoral
(n = 5354) P
VA bleed 2 (0.1) 17 (0.3) P = .12
lood transfusion 10 (0.6) 117 (2.3) 21.90, P b .0001
latelet transfusion 1 (0.06) 19 (0.37) 4.56, P = .03
etroperitoneal bleed 1 (0.06) 6 (0.12) 21.90, P b .0001
ther hemorrhage 11 (0.6) 8 (0.4) P = .08
otal bleed 25 (1.5) 167 (3.5) 17.58, P b .001
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of our knowledge, this is the first time that TRA access
site use utilization and its associated outcomes have been
studied from a national perspective.
The relationship that we have observed between
mortality/MACCE outcomes and access site utilization
does not infer causality. Our data suggest that TFA is used
in more clinically unstable patients, which may in part
contribute to the increased rates of mortality associated
with TFA. Although we have attempted to adjust for such
factors through the use of both multivariate analysis as well
as propensity score matching and inverse probability
weighting analysis, unmeasured confounders may contrib-
ute to residual case selection bias that cannot be completely
controlled for.
An important contributory mechanism that may account
for the observed association between TRA and 30-day
mortality is a lower rate of major bleeding complications
associated with the use of TRA. We show that utilization
of the TRA is independently associated with a 63% lower
risk of major bleeding complications in this high-risk
cohort. Similar, reductions in major bleeding complica-
tions have been reported in a cardiogenic shock cohort
through a reduction in access site–related bleeding
complications associated with TRA utilization.9V
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TMajor bleeding complications are an important cause
of mortality in patients with cardiogenic shock, with in-
hospital major bleeding rates reported to be as high as
37% in patients with cardiogenic shock in a contempo-
rary cohort of patients undergoing primary PCI.12
Similarly, in an analysis of 302,152 PCI procedures from
the National Cardiovascular Data Registry, the presence
of cardiogenic shock was associated with a 4-fold
increase in major bleedings rates.13 This increase in
major bleeding risk is related to several factors. Use of
IABP in contemporary PCI is one of the strongest
predictors of major bleeding complications. In the Global
Registry of Acute Coronary Events, the incidence of major
bleeding was 18% in those patients treated with IABP
compared to 3.5% in the remaining cohort, whilst in the
BCIS-1 study, use of the IABP bleeding complications
occurred in 19.2% of patients in the elective PCI setting.14
Abnormalities in platelet physiology15 and coagulation/
fibrinolysis pathways16 following the development of
cardiogenic shock may also contribute to the increase in
bleeding complications.
Major bleeding complications are a powerful
predictor of mortality,17 with a significant proportion of
major bleeding complications occurring through the
access site18; and utilization of TRA in PCI procedures is
associated with both a reduction in access site–related
major bleeding complications and mortality outcomes.19
In patients presenting with AMI and cardiogenic shock
treated with an IABP, utilization of bifemoral access has
been reported to almost double major bleeding complica-
tions compared to a single femoral puncture.20 Utilization of
TRA to limit the number of groin punctures needed in
cardiogenic shockpatientsmaybe an importantmechanism
to explain some of the beneficial effects we have observed.
Previous commentators have suggested that cardiogenic
shock remains the final frontier that has given even
experienced radial operators pause6; and even in the
very highest volume radial centers in the United Kingdom
where TRA rates exceed 75%, the TRAwas used in less than
half of procedures. A significant learning curve exists in
undertaking PCI procedures through the TRA, and patients
with cardiogenic shock represent the most complex and
hemodynamically unstable patients with significant tech-
nical challenges. Operators at the start of their learning
curve should consider the TFA as the default access site
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Indeed, in centers with the lowest rates of TRA adoption
(b25%), the favorable outcomes associated with the TRA
(compared to TFA) in mortality or MACCE were not
observed. This would be in keeping with findings from the
RIVAL study7 in which TRA was only associated with a
significant reduction in the primary composite end point
in the highest tertile volume radial centers. In such low-
volume radial centers (b25% TRA), it is not clear why 8% of
cardiogenic shock cases were still performed through the
TRA approach. It may have been related to the presence of
significant peripheral vascular disease preventing adoption
of the TFA in these cases or that the patientwasmore stable
at the start of the procedure, with hemodynamic compro-
mise and shock developing during the procedure.
Our analysis has several strengths. The BCIS data set
includes an almost complete collection of all PCI proce-
dures performed in the United Kingdom, reflecting a
national real-world experience that includesmanyhigh-risk
patients who are often excluded from randomized
controlled trials. This analysis includes N7,000 patients
and so represents the largest analysis of access site–related
outcomes in PCI procedures performed in patients with
cardiogenic shock in the literature to date.
However, as with any analysis of this kind, a number of
limitations exist. The diagnosis of cardiogenic shock is self-
reported by individual operators with no external valida-
tion, although our reported 30-day mortality rates of 36.3%
for our cohort are in line with those reported in other
contemporary cohorts,1,5,21 with similar 30-day mortality
rates as in the IABP-II SHOCK trial (40%),22 suggesting that
cardiogenic shock is not over- or underreported in our
study population. Similarly, our reported rate of cardiogen-
ic shock in patients undergoing PCI of 1.7% is similar to
rates reported in other large national data sets such as the
National Cardiovascular Data Registry dataset (2.1%).23
Secondly, althoughmortality tracking within the United
Kingdom is very robust, the cause of mortality is not
currently available; and all other outcomes and compli-
cations are self-reported and are not formally audited by
BCIS, which may mean that our analysis may be subject to
reporting biases.
Finally, although we have attempted to correct for
differences in baseline covariates between the TFA and
TRA groups using multivariate analysis, propensity score
matching, and inverse-probability weighting, unmea-
sured confounders may be present that contribute to
the unfavorable outcomes observed in the TFA cohort.
In conclusion, the current analysis of data derived from
the BCIS database of N7,000 PCI procedures performed in
the United Kingdom in patients with cardiogenic shock
shows that although the majority of PCI cases performed
in patients with cardiogenic shock in the United Kingdom
are performed through the TFA, the radial artery represents
an alternative viable access site in this high-risk cohort of
patients in experienced centers.Disclosures
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Variable Radial (n = 1402)
Age (y) 66.2 (65.5-66.9)
Gender (male, %) 1042 (74.3)
Diabetes (%) 261 (18.6)
Hypertension (%) 633 (45.2)
Hypercholesterolemia 617 (44.0)
PVD (%) 117 (8.4)
Renal failure (%) 76 (5.4)
Previous MI (%) 311 (22.2)
Previous PCI (%) 142 (10.2)
Previous CABG (%) 30 (2.1)
IABP (%) 356 (25.4)
Ventilated (%) 216 (15.4)
Data are means (95% CI) or percent (%). Differences between proportions used χ2 tests.femoral access site in propensity-matched cardiogenic shock cohort
Femoral (n = 1402) P
66.8 (66.1-67.4) .22
1037 (74.0) .83
237 (16.9) .24
598 (42.7) .18
600 (42.8) .52
115 (8.2) .89
66 (4.7) .39
281 (20.0) .17
211 (15.1) .001
32 (2.2) .80
346 (24.7) .66
239 (17.1) .24
